about
Adipocytes as immune cells: differential expression of TWEAK, BAFF, and APRIL and their receptors (Fn14, BAFF-R, TACI, and BCMA) at different stages of normal and pathological adipose tissue developmentIdentification of polyproline II regions derived from the proline-rich nuclear receptor coactivators PNRC and PNRC2: new insights for ERα coactivator interactions.BAFF, APRIL, TWEAK, BCMA, TACI and Fn14 proteins are related to human glioma tumor grade: immunohistochemistry and public microarray data meta-analysis.Expression of TNF-superfamily members BAFF and APRIL in breast cancer: immunohistochemical study in 52 invasive ductal breast carcinomas.ERα17p, a peptide reproducing the hinge region of the estrogen receptor α associates to biological membranes: A biophysical approach.TWEAK affects keratinocyte G2/M growth arrest and induces apoptosis through the translocation of the AIF protein to the nucleus.Early membrane initiated transcriptional effects of estrogens in breast cancer cells: First pharmacological evidence for a novel membrane estrogen receptor element (ERx).TPL2 kinase is a suppressor of lung carcinogenesisMembrane-initiated steroid action in breast and prostate cancer.Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung CancerNuclear IRF-1 expression as a mechanism to assess "Capability" to express PD-L1 and response to PD-1 therapy in metastatic melanoma.Interplay of estrogen receptors and GPR30 for the regulation of early membrane initiated transcriptional effects: A pharmacological approach.Recent insights into the effect of natural and environmental estrogens on mammary development and carcinogenesis.Novel oligomeric proanthocyanidin derivatives interact with membrane androgen sites and induce regression of hormone-independent prostate cancer.Estrogen anti-inflammatory activity on human monocytes is mediated through cross-talk between estrogen receptor ERα36 and GPR30/GPER1.Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.Whole transcriptome analysis of the ERα synthetic fragment P295-T311 (ERα17p) identifies specific ERα-isoform (ERα, ERα36)-dependent and -independent actions in breast cancer cells.ERα36, a new variant of the ERα is expressed in triple negative breast carcinomas and has a specific transcriptomic signature in breast cancer cell lines.ERα17p, an ERα P295 -T311 fragment, modifies the migration of breast cancer cells, through actin cytoskeleton rearrangements.The estrogen receptor alpha-derived peptide ERα17p (P(295)-T(311)) exerts pro-apoptotic actions in breast cancer cells in vitro and in vivo, independently from their ERα status.Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR.Androgen Control in Prostate Cancer.Effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes and PD-L1 expression in breast cancer and its clinical significance.Conjugated and non-conjugated androgens differentially modulate specific early gene transcription in breast cancer in a cell-specific manner.Quercetin accumulates in nuclear structures and triggers specific gene expression in epithelial cells.B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies.Erythropoietin and its receptor in breast cancer: correlation with steroid receptors and outcome.APRIL binding to BCMA activates a JNK2-FOXO3-GADD45 pathway and induces a G2/M cell growth arrest in liver cells.Detection of the TNFSF members BAFF, APRIL, TWEAK and their receptors in normal kidney and renal cell carcinomas.CD68, CD163, and matrix metalloproteinase 9 (MMP-9) co-localization in breast tumor microenvironment predicts survival differently in ER-positive and -negative cancersTumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial.
P50
Q24336188-76635EF8-E3C1-4321-A1BA-E93C513672C0Q30009591-AF8DDBF5-76DF-4564-8DEB-DC0DEAE70D8AQ30724766-82C66353-6558-4CA2-B91B-859CF9E867EBQ33325701-59007A42-4008-4122-B19B-955C883ED9FFQ34199023-1012556A-99DD-4812-9E44-3169B07B5722Q34206359-544B6F67-3940-418A-B37E-48C6AB9B3817Q34260314-83DE73F1-8D57-4476-A06A-34709DB12DB8Q36781882-38755FDB-5FB7-4F8B-ACC3-4E875AFBC13BQ37076999-8712A12F-9BF4-4752-8111-E7E6DE452345Q37087884-51649E13-7DC2-4DEE-A2C1-28F62B03A0E2Q37713503-4868CBA1-8752-4D99-A3B5-F2D95DA547A3Q37964372-059BFF90-202C-4FA0-9E3F-A9D512FD867CQ37967586-4DD624D3-473E-4293-A0CC-40D7C55E1365Q38465343-A8B96D09-37C7-49F4-A641-E3B787AB9234Q38833487-0FC8594D-56F2-4B91-8E6E-6634978713FEQ38859693-0F3B98B3-34AD-441F-8376-125AC99DF58CQ39183133-0B71749C-395F-41B0-A7E1-7C43CDEB41B9Q39422427-16BB1ABD-D79D-4F22-A1AB-AA9133DB10AAQ39492980-1777088F-0630-41C8-BED5-487C6AC59D1EQ39619285-6BF706F0-8DB8-4C42-8BA3-81E5712D8E91Q39734169-C84BFD30-03A7-42B9-9A4B-F5781CE74FF0Q39830515-B9466957-3D2F-4CFE-AF9C-1F1670A8F925Q41291930-DE9C9249-27FE-4D0E-9155-4F2C1EB5B973Q43254788-20C74222-954E-4BE7-9110-BA22EA34E5F5Q44088791-53C5DA11-3019-4C88-BC4D-06B37AD00683Q44958542-43AA1EE6-03CB-4413-BA57-E441F1D8ABC8Q46954244-8F258D40-1E2C-455B-8F67-015980D38FB3Q53139450-E4EAE3DE-1C53-4A0D-9E05-A8C0A6E5C1C6Q54315145-0C7C60D2-5B5E-4C8F-BCC0-72A85BCEEE92Q60044419-028ACA11-54C2-4999-8B18-20FEB8A60A7DQ64926812-FAC027D3-640A-40EF-9835-7DC40D145CA0
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Vassiliki Pelekanou
@ast
Vassiliki Pelekanou
@en
Vassiliki Pelekanou
@es
Vassiliki Pelekanou
@nl
type
label
Vassiliki Pelekanou
@ast
Vassiliki Pelekanou
@en
Vassiliki Pelekanou
@es
Vassiliki Pelekanou
@nl
prefLabel
Vassiliki Pelekanou
@ast
Vassiliki Pelekanou
@en
Vassiliki Pelekanou
@es
Vassiliki Pelekanou
@nl
P106
P1153
22938913900
P31
P496
0000-0002-8431-1927